PROK - NASDAQ
ProKidney Corp.
$1.73
-8.9%ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
At a Glance
Live SnapshotProKidney Corp. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
ProKidney Corp. Cash Flow Statement
PROK • NASDAQ
| ProKidney Corp. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-151.6M | -163.3M | -135.4M | -148.1M | -55.1M | -26.7M | -79.6K | |
6.6M | 5.4M | 3.9M | 3M | 2M | 964K | 867.0 | |
25.3M | 29.4M | 30.8M | 74.5M | 699K | 730K | 498.0 | |
-1.7M | -1.8M | -6M | 0.0 | 0.0 | 0.0 | 1.6K | |
(0.0) | (73K) | (2.9M) | (2M) | (68K) | (145K) | (0.0) | |
1.3M | 4M | 16.7M | -6.5M | 2.2M | -126K | -115.0 | |
-120.1M | -126.4M | -90.1M | -77.1M | -50.3M | -25.2M | -76.8K | |
INVESTING ACTIVITIES | |||||||
-15.2M | -29.5M | -34.2M | -1.8M | -5.2M | -5.5M | -1.3K | |
(18.2M) | (0.0) | (0.0) | (108K) | (1K) | (0.0) | -1.7K | |
-217.1M | -324M | -471.6M | (0.0) | (0.0) | (0.0) | (0.0) | |
318M | 373.9M | 175.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
(104M) | (20.4M) | -330M | -1.7M | -5.2M | -5.5M | -3K | |
FINANCING ACTIVITIES | |||||||
25.6M | 144.3M | -9.5M | 6.1M | 71.5M | 0.0 | 0.0 | |
-26K | -54K | -52K | -32K | -30K | -11K | 0.0 | |
(0.0) | (0.0) | -9.5M | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 140K | 0.0 | 542.5M | 0.0 | 20M | 20K | |
25.6M | 144.4M | -9.6M | 548.5M | 71.5M | 20M | 20K | |
CASH FLOW SUMMARY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 75K | |
9.4M | 38.5M | -429.6M | 469.7M | 16M | -10.6M | 15.2K | |
99.1M | 60.6M | 490.3M | 20.6M | 4.6M | 15.2M | 0.0 | |
108.5M | 99.1M | 60.6M | 490.3M | 20.6M | 4.6M | 15.2K | |
-135.3M | -155.9M | -124.3M | -78.9M | -55.5M | -30.6M | -78.1K |
SEC Filings
PROK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 18, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 02, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your PROK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.